Novo Nordisk signs licensing deal with Orbis Medicines worth up to $1.4 billion
The agreement gives Novo Nordisk access to Orbis Medicines' technology in a deal valued at as much as $1.4 billion.
TR
By Tom Reyes · Markets Editor
Sep 17 09:56 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk entered a licensing agreement with Orbis Medicines carrying potential value up to $1.4 billion.
- 02Signals continued Novo dealmaking to expand its metabolic and oral drug pipeline.
- 03Specific targets, milestone terms and timelines were not detailed.
From the source
Read at news.google.comNovo Nordisk Signs Up To $1.4 Billion Licensing Deal With Orbis Medicines